News

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets.  ImmunoForge will be responsible […]

  Lille, 5 December 2018 – Elasmogen wins another prestigious award during the 7th Edition of BioFIT. BioFIT is one of Europe’s leading business conventions for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences. It is also becoming an important marketplace for seed investment in Life Sciences by facilitating early-stage financing deals and gives participants an opportunity to access information about current events and trends in […]

Elasmogen’s CEO Dr Caroline Barelle won the Academic Entrepreneur of the Year award at Entrepreneurial Scotland’s Summit Awards ceremony which took place on 22nd November 2018 in Glasgow. Commenting on her win, Caroline says “I am delighted to be recognised for championing science-led enterprise at a national level. It is a fantastic achievement, and there […]

Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an individual who has demonstrated an enterprising approach to developing and delivering enterprise and entrepreneurial learning and skills, inspiring students and enabling them to realise their enterprise potential. The Academic to Entrepreneur […]

Our CEO Caroline Barelle was interviewed by Scottish Business News Network. In her interview, Caroline discusses the journey of starting up Elasmogen and provides an insight into the ups and downs of those early days alongside a glimpse into where Elasmogen is now and the future of the company. Read the full interview here Caroline […]

£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen, an SME focused on the development of next generation biologics, announced today that they have been awarded […]

17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising Stars: Extraordinary Talent (2017)” category at last night’s Scotland’s Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland’s top Life […]

Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and business leaders have been shortlisted for the prestigious Scottish Life Sciences Awards 2018. Read more here

Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets   Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop […]